Government-Owned Inventions; Availability for Licensing, 80082 [2016-27337]

Download as PDF 80082 Federal Register / Vol. 81, No. 220 / Tuesday, November 15, 2016 / Notices Dated: November 8, 2016. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–27336 Filed 11–14–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Closed Meetings mstockstill on DSK3G9T082PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Mental Health Special Emphasis Panel; Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions. Date: November 30, 2016. Time: 11:30 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6100 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Karen Gavin-Evans, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH Neuroscience Center, 6001 Executive Boulevard, Room 6153, MSC 9606, Bethesda, MD 20892, 301–451–2356, gavinevanskm@mail.nih.gov. Time: 8:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: David I. Sommers, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, 6001 Executive Blvd., Room 6154, MSC 9606, Bethesda, MD 20892–9606, 301–443–7861, dsommers@mail.nih.gov. Name of Committee: National Institute of Mental Health Special Emphasis Panel, NIMH Fellowship and Dissertation Research Review Teleconference. Date: December 1, 2016. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. VerDate Sep<11>2014 22:00 Nov 11, 2016 Jkt 241001 Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Vinod Charles, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH Neuroscience Center, 6001 Executive Blvd., Room 6151, MSC 9606, Bethesda, MD 20892–9606, 301–443–1606, charlesvi@mail.nih.gov. Time: 12:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: David W. Miller, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH Neuroscience Center, 6001 Executive BLVD, Room 6140, MSC 9608, Bethesda, MD 20892–9608, 301–443– 9734, millerda@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS) Dated: November 8, 2016. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–27341 Filed 11–14–16; 8:45 am] BILLING CODE 4140–01–P be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: Technology descriptions follow. Immortalized Stria Vascularis Cell Line SV–k1 Description of Technology Available for nonexclusive licensing for research uses is the cell line, SV–k1, derived from the Organ of Corti. The line was developed from the stria vascularis, an organ localized on the lateral wall of the cochlea, adjacent to the Organ of Corti, containing cell populations specialized in the production of an endolymph very rich in K+ characteristic of the mammalian inner ear. SV–k1 cells express a set of biomarkers completely different of those expressed by OC–k3 cells (See notice for E–012–2017/0 published contemporaneously herewith), and are not sensitive to ototoxic drugs. Potential Commercial Applications • Research • Hearing research Development Stage • Materials DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the National Heart, Lung and Blood Institute, Office of Technology Transfer and Development, National Institutes of Health, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may SUMMARY: PO 00000 Frm 00068 Fmt 4703 Sfmt 9990 Inventors Gilda Mabel Canseco de Kalinec and Federico Kalinec (both of NIDCD). Publications 1. Espreafico, EM et al., ‘‘Localization of Myosin-V in the Centrosome’’ (1998) Proc Nat’l Acad Sci USA 95(15):8636–8641, 1998. 2. Gratton MA et al., ‘‘Strial marginal cells play a role in basement membrane homeostasis: In vitro and in vivo evidence.’’ Hear Res 163:27–36, 2002. 3. Park, C., et al., ‘‘HEl-OC1 Cells as a Model for Investigating Prestin Function.’’ (2016) Hear Res 335:9– 17. Intellectual Property HHS Reference No. E–013–2017/0— Research Material. Licensing Contact Michael Shmilovich, Esq, CLP; 301– 435–5019; shmilovm@mail.nih.gov. Dated: November 7, 2016. Michael Shmilovich, National Heart, Lung and Blood Institute, Office of Technology Transfer and Development, National Institutes of Health. [FR Doc. 2016–27337 Filed 11–14–16; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\15NON1.SGM 15NON1

Agencies

[Federal Register Volume 81, Number 220 (Tuesday, November 15, 2016)]
[Notices]
[Page 80082]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-27337]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of federally-funded research and development. Foreign 
patent applications are filed on selected inventions to extend market 
coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the National Heart, Lung and Blood 
Institute, Office of Technology Transfer and Development, National 
Institutes of Health, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 
20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

Immortalized Stria Vascularis Cell Line SV-k1

Description of Technology

    Available for nonexclusive licensing for research uses is the cell 
line, SV-k1, derived from the Organ of Corti. The line was developed 
from the stria vascularis, an organ localized on the lateral wall of 
the cochlea, adjacent to the Organ of Corti, containing cell 
populations specialized in the production of an endolymph very rich in 
K\+\ characteristic of the mammalian inner ear. SV-k1 cells express a 
set of biomarkers completely different of those expressed by OC-k3 
cells (See notice for E-012-2017/0 published contemporaneously 
herewith), and are not sensitive to ototoxic drugs.

Potential Commercial Applications

     Research
     Hearing research

Development Stage

     Materials

Inventors

Gilda Mabel Canseco de Kalinec and Federico Kalinec (both of NIDCD).

Publications

1. Espreafico, EM et al., ``Localization of Myosin-V in the 
Centrosome'' (1998) Proc Nat'l Acad Sci USA 95(15):8636-8641, 1998.
2. Gratton MA et al., ``Strial marginal cells play a role in basement 
membrane homeostasis: In vitro and in vivo evidence.'' Hear Res 163:27-
36, 2002.
3. Park, C., et al., ``HEl-OC1 Cells as a Model for Investigating 
Prestin Function.'' (2016) Hear Res 335:9-17.

Intellectual Property

    HHS Reference No. E-013-2017/0--Research Material.

Licensing Contact

    Michael Shmilovich, Esq, CLP; 301-435-5019; shmilovm@mail.nih.gov.

    Dated: November 7, 2016.
Michael Shmilovich,
National Heart, Lung and Blood Institute, Office of Technology Transfer 
and Development, National Institutes of Health.
[FR Doc. 2016-27337 Filed 11-14-16; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.